Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.
Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision v3.3.3 was added. HHS Vulnerability Disclosure and Revision v3.3.2 were removed.SummaryDifference0.2%
- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe study record history now includes revision v3.3.2 and removes v3.3.1, updating the version history without changing core trial data.SummaryDifference0.1%
- Check43 days agoChange DetectedThe Record History now includes a new revision entry (v3.3.1) and removes the previous revision (v3.2.0), a change limited to the audit trail and not affecting study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check50 days agoChange DetectedA government funding notice about potential delays and operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%
- Check64 days agoChange DetectedThe history page shows newer version entries and metadata updates, while the core study details remain unchanged.SummaryDifference0.1%
- Check93 days agoChange DetectedDifference12%
Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.